MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Geron Company Profile (NASDAQ:GERN)

Consensus Ratings for Geron (NASDAQ:GERN) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.80 (162.55% upside)

Analysts' Ratings History for Geron (NASDAQ:GERN)
Show:
DateFirmActionRatingPrice TargetActions
5/8/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015OppenheimerReiterated RatingBuy$5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Geron (NASDAQ:GERN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.12$0.17$17.87 million$35.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.06)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.07)($0.07)$0.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312($0.14)($0.13)$0.38 million$0.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Geron (NASDAQ:GERN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Geron (NASDAQ:GERN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Geron (NASDAQ:GERN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Geron (NASDAQ:GERN)
DateHeadline
06/22/16 08:50 AMEye Catching Stocks - Marathon Oil Corporation, (NYSE:MRO), Geron Corporation, (NASDAQ:GERN) - Hot Stocks Point
06/20/16 01:28 PMETF’s with exposure to Geron Corp. : June 20, 2016 -
06/19/16 03:53 PMGeron Corporation (NASDAQ:GERN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 03:46 PM9 Easy Ways to Lose Money in the Stock Market - Motley Fool
06/17/16 04:03 PMBiotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
06/16/16 08:31 AMAnalysts: Geron Corporation (NASDAQ:GERN) stock is worth $7.5 - iStreetWire
06/06/16 04:30 PMETF’s with exposure to Geron Corp. : June 6, 2016 -
06/06/16 04:02 PMWhich way Geron Corp. (NASDAQ:GERN) insiders are heading - iStreetWire
06/02/16 07:16 AMGeron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : June 2, 2016 -
06/02/16 07:16 AMGeron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : June 2, 2016 -
06/01/16 04:29 PMThe Outlook For Geron Corporation's Oncology Program - Seeking Alpha - Seeking AlphaThe Outlook For Geron Corporation's Oncology ProgramSeeking AlphaGeron Corporation (NASDAQ:GERN) made big splashes years ago by being the first company to receive approval to move a stem cell transplant therapy into clinical trials. Several years later, the company decided to focus its efforts on development of ...Recently Changed Price Targets On Geron Corporation (NASDAQ:GERN)Risers & Fallersall 4 news articles »
06/01/16 04:29 PMThe Outlook For Geron Corporation's Oncology Program - Seeking Alpha - Seeking AlphaThe Outlook For Geron Corporation's Oncology ProgramSeeking AlphaGeron Corporation (NASDAQ:GERN) made big splashes years ago by being the first company to receive approval to move a stem cell transplant therapy into clinical trials. Several years later, the company decided to focus its efforts on development of ...Recently Changed Price Targets On Geron Corporation (NASDAQ:GERN)Risers & Fallersall 4 news articles »
06/01/16 05:15 AMA Milestone Event In Geron's Imetelstat Phase II Study For Myelofibrosis Patients May Be Imminent - Geron (NASDAQ:GERN) CEO Dr. John (Skip) Scarlett recently provided investors ... The 4.7 mg dosage is the lowest dosage where the company predicts Telomerase inhibition would occur. Dr. Scarlett confirmed that the 9.4 mg dosage provided the best risk ...
05/30/16 12:39 AMGeron Co. (GERN) Earns Buy Rating from FBR & Co. - Let Me Know About This - Geron Co. (GERN) Earns Buy Rating from FBR & Co.Let Me Know About ThisGeron Co. (NASDAQ:GERN)'s stock had its “buy” rating reissued by investment analysts at FBR & Co. in a research report issued on Sunday. Geron (NASDAQ:GERN) traded up 1.42% during mid-day trading on Friday, reaching $2.85. The company had a ...
05/27/16 02:32 PMGeron Corporation (NASDAQ:GERN): Updated Analyst Ratings - iStreetWire - Geron Corporation (NASDAQ:GERN): Updated Analyst RatingsiStreetWireGeron Corporation (GERN) up 4.63 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who ...and more »
05/19/16 07:29 PMLatest Geron Corporation (NASDAQ:GERN) Target Price Suggests Stock Is Worth $7.5/Share - Street Register - News OracleLatest Geron Corporation (NASDAQ:GERN) Target Price Suggests Stock Is Worth $7.5/ShareStreet RegisterGeron Corporation (GERN) up 2.18 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who ...Geron Corporation (NASDAQ:GERN) Analyst ReviewRisers & Fallersall 9 news articles »
05/19/16 04:02 PMGERON CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 09:31 PMETF’s with exposure to Geron Corp. : May 19, 2016 -
05/16/16 10:09 AMGeron Corp. :GERN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/15/16 02:37 PMNext Weeks Broker Price Targets For Geron Corporation (NASDAQ:GERN) - Share Trading News - Next Weeks Broker Price Targets For Geron Corporation (NASDAQ:GERN)Share Trading NewsGeron Corporation has a 50 day moving average of 3.02 and a 200 day moving average of 3.46. The stock's market capitalization is 419.65M, it has a 52-week low of 2.30 and a 52-week high of 5.30. The share price of the company (NASDAQ:GERN) was up ...and more »
05/08/16 10:15 AMCan Geron Shares Still Ultimately Double? -
05/06/16 12:06 PMEdited Transcript of GERN earnings conference call or presentation 5-May-16 8:30pm GMT -
05/06/16 07:18 AMGeron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus -
05/05/16 07:43 PMGeron's (GERN) CEO John Scarlett on Q1 2016 Results - Earnings Call Transcript - And welcome to the Geron First Quarter 2016 Earnings Conference Call ... I will now turn the call over to Chip to review current company events. Chip? Thanks, Olivia, good afternoon everyone and thanks for joining. I’ll begin with comments on the ...
05/05/16 04:17 PMETF’s with exposure to Geron Corp. : May 5, 2016 -
05/05/16 03:30 PMGeron Corp Earnings Call scheduled for 4:30 pm ET today -
05/05/16 03:27 PMGERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/05/16 03:05 PMGERON CORP Files SEC form 10-Q, Quarterly Report -
05/05/16 03:05 PMGeron Corporation Reports First Quarter 2016 Financial Results and Recent Events - [GlobeNewswire] - MENLO PARK, Calif., May 05, 2016-- Geron Corporation today reported financial results for the first quarter ended March 31, 2016 and recent events.. For the first quarter of 2016, the company reported ...
05/05/16 06:07 AMQ1 2016 Geron Corp Earnings Release - After Market Close -
05/04/16 07:43 PMGeron Corporation (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Study Released - Geron Corporation (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information ...
05/04/16 08:10 AMGeron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : May 4, 2016 -
05/03/16 08:20 AMGeron (GERN) Q1 Earnings: What's in Store for the Stock? -
05/02/16 02:37 PMGeron Corporation (NASDAQ:GERN) Broker Price Targets For The Coming Week - Share Trading News - Geron Corporation (NASDAQ:GERN) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Geron Corporation (NASDAQ:GERN). The latest reports which are currently in issue on Monday 2nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
04/28/16 02:38 PMMomentum Stocks in Focus: Sony Corporation (SNE), Geron Corporation (GERN), Ford Motor Co. (F) - iStreetWire - Momentum Stocks in Focus: Sony Corporation (SNE), Geron Corporation (GERN), Ford Motor Co. (F)iStreetWireSony Corporation (SNE) continued its downward trend with the stock declining -0.62% or $-0.16 to close the day at $25.61 on light trading volume of 1.11M shares, compared to its three month average trading volume of 1.61M. The Tokyo Tokyo 108 based ...
04/27/16 06:51 AMGeron Announces Conference Call to Discuss First Quarter 2016 Financial Results - [at noodls] - MENLO PARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the first quarter ended March 31, 2016, on Thursday, May 5, 2016, after the ...
04/24/16 01:59 PMAre These 3 Biotechs Destined to Be Bought Out? -
04/21/16 06:47 AMWhy one trader is buying puts in Geron -
04/20/16 06:41 AMGeron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting - [at noodls] - MENLO PARK, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, ...
04/20/16 06:36 AM7:36 am Geron announces two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 AACR Meeting -
04/15/16 02:32 PMGeron Corporation (NASDAQ:GERN) Updated Broker Price Targets - Share Trading News - Geron Corporation (NASDAQ:GERN) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Geron Corporation (NASDAQ:GERN). The latest reports which are currently in issue on Friday 15th of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
04/14/16 02:36 PMGeron Co. (GERN) Short Interest Update - Washington News Wire - Washington News WireGeron Co. (GERN) Short Interest UpdateWashington News WireGeron logo Geron Co. (NASDAQ:GERN) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 31,565,531 shares, an increase of 4.4% from the March 15th total of 30,243,921 shares, Market ...and more »
04/08/16 07:42 PMCurrent Price Targets For Geron Corporation (NASDAQ:GERN) - Risers & Fallers - Current Price Targets For Geron Corporation (NASDAQ:GERN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Geron Corporation (NASDAQ:GERN). The latest broker reports which are currently outstanding on Friday 8th of April state 2 analysts have a rating of “strong buy”, 1 ...and more »
04/08/16 02:34 PM3 Stocks to Watch For: Century Aluminum Co. (CENX), Geron Corporation (GERN), FMC Technologies, Inc. (FTI) - iStreetWire - 3 Stocks to Watch For: Century Aluminum Co. (CENX), Geron Corporation (GERN), FMC Technologies, Inc. (FTI)iStreetWireGeron Corporation (GERN) shares were down in last trading by -2.74% to $3.2. It experienced lighter than average volume on day. The stock increased in value by almost 9.59% over the past week and grew 10.73% in the past month. It is currently trading ...and more »
04/07/16 09:21 AM3 Likely Reasons Why Geron Corporation Vaulted Higher By 18% in March - Is Geron's bounce temporary or the start of something much bigger?
04/05/16 06:48 AMGeron to Present at the Needham Healthcare Conference - [at noodls] - MENLO PARK, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the ...
04/04/16 02:28 PMUpgrades And Downgrades For Geron Corporation (NASDAQ:GERN) - Risers & Fallers - Upgrades And Downgrades For Geron Corporation (NASDAQ:GERN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Geron Corporation (NASDAQ:GERN). The latest broker reports which are currently outstanding on Monday 4th of April state 2 analysts have a rating of “strong buy”, 1 ...and more »
04/03/16 02:24 PMAfter Last Week What Do Analysts Think Of Geron Corporation (NASDAQ:GERN) - Share Trading News - After Last Week What Do Analysts Think Of Geron Corporation (NASDAQ:GERN)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Geron Corporation (NASDAQ:GERN). According to data from Reuters, 2 analysts have a rating of “buy”, 1 analysts “outperform”, 2 analysts “hold”, 0 ...and more »
04/01/16 02:32 PMAnalyst Review: Geron Corporation (NASDAQ:GERN) - Risers & Fallers - Analyst Review: Geron Corporation (NASDAQ:GERN)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Geron Corporation (NASDAQ:GERN). According to the latest broker reports outstanding on Friday 1st of April, 2 analysts have a rating of “strong buy”, 1 analysts “buy ...and more »
03/30/16 09:29 AMWhy Investors Are So Bullish on This Small Biotech - [Accesswire] - LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The ...
About Geron

Geron logoGeron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GERN
  • CUSIP: 37416310
Key Metrics:
  • Previous Close: $2.59
  • 50 Day Moving Average: $2.80
  • 200 Day Moving Average: $3.18
  • P/E Ratio: 863.33
  • P/E Growth: -2.12
  • Market Cap: $411.71M
  • Current Quarter EPS Consensus Estimate: $-0.26 EPS
Additional Links:
Geron (NASDAQ:GERN) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha